Aditxt Inc Stock Price, News & Analysis

Aditxt Inc (NASDAQ: ADTX) announced a Weekly Update event focusing on its subsidiary Pearsanta's recent acquisition of the CaSe Platform, a proprietary technology based on adductomics. The platform is designed to detect early DNA changes that may lead to cancer-associated mutations and other illnesses.

The virtual event, scheduled for March 28, 2025, at 11:30 a.m. ET, will feature presentations from key figures including Dr. Shahrokh Shabahang (Aditxt's Chief Innovation Officer), Chris Mitton (Pearsanta's President), and Dr. Roger Giese (Co-Inventor of the CaSe Platform and Professor Emeritus at Northeastern University). The discussion will explore the platform's potential role in advancing early cancer detection and prevention efforts.

Evofem Biosciences (OTCQB: EVFM) reported its financial results for Q4 and full-year 2024, marking its fourth consecutive year of net sales growth. The company achieved $19.4 million in net sales for 2024, a 6% increase from 2023, primarily driven by PHEXXI® sales and improved gross-to-net ratio.

Key operational highlights include:

• Total operating expense reduced by 27% to $26.4 million (excluding SOLOSEC amortization)
• Sales and marketing expense at 47% of net sales for 2024, the best ratio since PHEXXI's launch
• Loss from operations improved by 57% to $7.7 million
• Revenue stream diversified through SOLOSEC® acquisition in July 2024

The company entered a fifth amendment to the merger agreement with Aditxt (NASDAQ: ADTX), requiring $1.5 million funding by April 7, 2025, and merger consummation by September 30, 2025. Additionally, Evofem partnered with Windtree Therapeutics to reduce PHEXXI manufacturing costs.

Aditxt (NASDAQ: ADTX) announced that its subsidiary Pearsanta has acquired key patents for adductomics-based DNA damage detection in a transaction valued at approximately $1 million, paid in Pearsanta Convertible Preferred Stock.

The acquisition enhances Pearsanta's cancer prevention diagnostic capabilities by combining with their proprietary Mitomic® Technology platform. The adductomics technology enables detection of DNA adducts - chemical modifications to DNA caused by carcinogens - which are early indicators of cancer risk. The platform will analyze urine, blood, or solid tissue samples to assess genomic instability before permanent mutations occur.

Over the next 2-3 years, Pearsanta plans to:

• Conduct clinical validation of the technology
• Submit regulatory applications for Laboratory Developed Tests (LDTs) and FDA pathways
• Scale operations within CLIA/CAP-certified laboratories
• Integrate adductomics-based screening into their precision oncology portfolio

Aditxt (NASDAQ: ADTX) provided a corporate update highlighting progress across its subsidiaries and strategic initiatives. The company announced the launch of Aditxt Weekly Updates starting March 21, 2025.

Key subsidiary updates include:

• Adimune™ is preparing IND applications for Stiff Person Syndrome with Mayo Clinic and Clinical Trial Applications for Type 1 Diabetes and Psoriasis in Germany
• Pearsanta™ is advancing toward commercial launch in H2 2025 for blood-based Prostate Cancer and Endometriosis tests, with Dominari Securities engaged for planned IPO
• Adivue™ plans to seek FDA renewal for Brain Scientific's EEG device

Strategic acquisition updates:

• Extended agreement with Appili Therapeutics through March 2025 with completed $250,000 payments
• Ongoing discussions with Evofem Biosciences for potential integration

The company recently implemented a reverse stock split to maintain Nasdaq compliance.

Aditxt (NASDAQ: ADTX) has announced a 1-for-250 reverse stock split effective March 17, 2025, on the Nasdaq Capital Market. The split was approved by stockholders at a special meeting on February 28, 2025, with the final ratio determined by the board of directors.

Following the reverse split, every 250 shares of common stock will be consolidated into 1 share, with fractional shares rounded up. The company will maintain its ADTX trading symbol but will receive a new CUSIP number: 007025802. Post-split, Aditxt will have approximately 1,031,110 shares of common stock outstanding.

The primary purpose of this corporate action is to achieve compliance with Nasdaq's minimum bid price requirement.

Aditxt (NASDAQ: ADTX) subsidiary Adimune has completed preclinical studies for ADI-100, its investigational immune modulation therapy targeting Psoriasis, Type 1 Diabetes (T1D), and Stiff Person Syndrome. The company plans to ship drug substances for final formulation in March.

Key preclinical findings show:

• Durable tolerance restoration over 10-month T1D studies in prevention and treatment
• No drug toxicity or antibody formation
• No impairment of immune system response against infection, cancer, or tumor-fighting capabilities

GMP clinical-grade drug substances have been manufactured, with two remaining drug product release assays in final validation stages. Adimune has completed additional studies requested by German regulators and engaged a CRO for clinical trials in Germany. The company is also preparing an IND package for FDA submission, with a pre-IND meeting expected in Q2.

Aditxt (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, has engaged Dominari Securities as lead underwriter for its planned IPO, targeted for H2 2025. The IPO aims to support Pearsanta's commercial launch of early cancer detection technology in the U.S. and internationally.

Pearsanta is developing a non-invasive blood-based test using proprietary Mitomic® Technology, which utilizes mitochondrial DNA deletions as biomarkers for disease detection. The company is currently advancing clinical validation, including a randomized controlled study of the Mitomic Prostate Test (MPT).

The company has submitted two research proposals: a $2.3M proposal to evaluate MPT's role in reducing unnecessary biopsies, with a decision expected in H1 2025, and a $1.1M proposal for validating the Mitomic Ovarian Test (MOT), which was not funded. IPO proceeds will fund the U.S. launch of Laboratory Developed Tests and drive global commercialization through partnerships and regulatory approvals.

Aditxt (NASDAQ: ADTX) has announced a virtual Fireside Chat scheduled for Friday, February 21, 2025, at 11:30 AM Eastern Time. CEO Amro Albanna will lead the session, providing updates on key corporate developments and the company's pipeline.

The discussion will focus on two main areas: Adimune, a subsidiary working on autoimmune conditions including Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome, and Pearsanta's early cancer detection program and its planned IPO for 2025.

Participants can submit questions via email to engagement@aditxt.com by February 20th at 5:00 PM ET. Registration is available through the provided Zoom webinar link.

Aditxt (NASDAQ: ADTX) announced its Board of Directors has approved exploring an Initial Public Offering (IPO) for its subsidiary, Pearsanta, targeted for 2025. Pearsanta, a precision diagnostic company, specializes in early cancer detection through its proprietary Mitomic® Technology platform.

The proposed IPO aims to provide resources for Pearsanta's growth and expand its market presence globally. The company focuses on developing and commercializing early cancer detection solutions to support healthcare professionals in providing earlier and more accurate diagnoses.

This strategic move aligns with Aditxt's mission to accelerate promising health innovations and positions Pearsanta for a successful global launch of its cancer detection platform.